ALESSANDRA FITZPATRICK: Open Payments
NPI 1346749900 · BETHESDA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$781 in 30 payments from 17 companies in 2025. Trend: 2023 $332 · 2024 $468 · 2025 $781
Food & beverage: $681Education: $100
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 2 | $120 |
| Novartis Pharmaceuticals Corporation | 5 | $115 |
| ABBVIE INC. | 4 | $107 |
| GlaxoSmithKline, LLC. | 2 | $66 |
| Merck Sharp & Dohme LLC | 2 | $48 |
| Alnylam Pharmaceuticals Inc. | 3 | $48 |
| PFIZER INC. | 2 | $44 |
| PharmaEssentia USA Corporation | 1 | $33 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $25 |
Products named: ERLEADA, SCEMBLIX, EPKINLY, OJJAARA, BESREMI, BLENREP, IMBRUVICA, AMVUTTRA.
Industry payments across MD — which companies pay providers there.
